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Abstract
Genome-wide association studies have identified numerous genetic loci for spirometic measures of pulmonary function,
forced expiratory volume in one second (FEV1), and its ratio to forced vital capacity (FEV1/FVC). Given that cigarette smoking
adversely affects pulmonary function, we conducted genome-wide joint meta-analyses (JMA) of single nucleotide
polymorphism (SNP) and SNP-by-smoking (ever-smoking or pack-years) associations on FEV1 and FEV1/FVC across 19
studies (total N = 50,047). We identified three novel loci not previously associated with pulmonary function. SNPs in or near
DNER (smallest PJMA=5.00610
211), HLA-DQB1 and HLA-DQA2 (smallest PJMA=4.35610
29), and KCNJ2 and SOX9 (smallest
PJMA=1.28610
28) were associated with FEV1/FVC or FEV1 in meta-analysis models including SNP main effects, smoking main
effects, and SNP-by-smoking (ever-smoking or pack-years) interaction. The HLA region has been widely implicated for
autoimmune and lung phenotypes, unlike the other novel loci, which have not been widely implicated. We evaluated DNER,
KCNJ2, and SOX9 and found them to be expressed in human lung tissue. DNER and SOX9 further showed evidence of
differential expression in human airway epithelium in smokers compared to non-smokers. Our findings demonstrated that
joint testing of SNP and SNP-by-environment interaction identified novel loci associated with complex traits that are missed
when considering only the genetic main effects.
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Introduction
Spirometric measures of pulmonary function, particularly
forced expiratory volume in one second (FEV1) and its ratio to
forced vital capacity (FEV1/FVC), are important clinical tools
for diagnosing pulmonary disease, classifying its severity, and
evaluating its progression over time. These measures also
predict other morbidities and mortality in the general
population [1–3]. Genetic factors likely play a prominent role
in determining the maximal level of pulmonary function in
early adulthood and its subsequent decline with age [4,5]. A
relatively uncommon deficiency of a-1 antitrypsin, due to
homozygous mutations of the SERPINA1 gene, is a well-
established genetic risk factor for accelerated decline in
pulmonary function, but it accounts for little of the population
variability in pulmonary function.
Genome-wide association studies (GWAS) have identified many
common genetic variants underlying pulmonary function. The
first GWAS of pulmonary function implicated HHIP for FEV1/
FVC [6,7]. GWAS meta-analyses for FEV1/FVC and FEV1 from
the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) and SpiroMeta Consortia have togeth-
er identified 26 additional novel loci in or near the following genes:
ADAM19, AGER-PPT2, ARMC2, C10orf11, CCDC38, CDC123,
CFDP1, FAM13A, GPR126, HDAC4, HTR4, INTS12-GSTCD-
NPNT, KCNE2, LRP1, MECOM (EVI1), MFAP2, MMP15, NCR3,
PID1, PTCH1, RARB, SPATA9, TGFB2, THSD4, TNS1, and
ZKSCAN3 [8–10].
Inhaled pollutants, especially cigarette smoking, can have
important adverse effects on pulmonary function. Candidate gene
studies have not consistently identified interactions with cigarette
smoking in relation to pulmonary function. Despite the importance
of smoking and other environmental factors in the etiology of many
complex human diseases and traits, few GWAS have incorporated
gene-by-environment interactions [11–14]. Meta-analyses are
generally necessary to provide sufficient sample size to detect
moderate effects, and methods for joint testing of single nucleotide
polymorphism (SNP) main effects and SNP-by-environment
interactions in the meta-analysis setting have only recently been
developed [15,16]. This strategy has the potential to identify novel
loci that would not emerge from analyses based on the SNP main or
interactive effects alone [15–17]. The well-documented and
consistent deleterious effect of cigarette smoking on pulmonary
function [18] makes it a good candidate for such an approach, since
genetic factors may have heterogeneous effects on pulmonary
function depending on smoking exposure. We conducted genome-
SNP and SNP-by-Smoking Analysis for Lung Function
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wide joint meta-analyses (JMA) of SNP and SNP-by-smoking
interaction (ever-smoking or pack-years) associations with cross-
sectional pulmonary function measures (FEV1/FVC and FEV1) in
50,047 study participants of European ancestry.
Results
Table S1 presents characteristics of the 50,047 participants from
19 studies contributing to our analyses. As expected, mean FEV1
and FVC values were lower in studies with the oldest participants.
Standardized residuals of FEV1 and FEV1/FVC (see Methods)
were used as the phenotypes for the JMA, in order to maximize
comparability with our recent GWAS meta-analysis from the
CHARGE and SpiroMeta Consortia [10]. Our original GWAS
meta-analyses, conducted separately in CHARGE and SpiroMeta,
showed that we were able to identify replicable genetic loci
whether using actual pulmonary function measures [8] or their
standardized residuals [9]. The standardized residual approach
was similarly taken in GWAS of other complex quantitative traits,
such as height and body mass index from the Genetic Investigation
of ANthropometric Traits (GIANT) Consortium [19,20].
In each of the 19 studies, four regression models with differing
SNP-by-smoking interaction terms were run: (1) SNP-by-ever-
smoking for standardized FEV1/FVC residuals, (2) SNP-by-pack-
years for standardized FEV1/FVC residuals, (3) SNP-by-ever-
smoking for standardized FEV1 residuals, and (4) SNP-by-pack-
years for standardized FEV1 residuals. Study-specific genomic
inflation factors (lgc) were calculated for the 1 degree-of-freedom
(d.f.) SNP-by-smoking interaction term, to ensure that there was
no substantial inflation due to the main effect of smoking being
misspecified [21]. All study-specific results had 1 d.f. lgc#1.09
(Table S2), which is of comparable magnitude to other studies with
large sample sizes [10,19,22,23].
The study-specific regression coefficients from each of the four
models were then combined in JMA, and the resulting lgc values
from the 2 d.f. JMA, calculated across all SNPs, ranged from 1.056
to 1.064. The quantile-quantile plots (Figure S1) show substantial
deviation from expectation for SNPs having low P values from the
JMA (PJMA). The JMA results corresponding to the top SNP from
each previously implicated locus [8–10] are presented in Table S3.
To identify novel loci among the genome-wide significant loci
implicated by our JMA models, the genomic regions surrounding
the most significant SNP from each of the 27 previously implicated
loci [8–10] (500 kb upstream to 500 kb downstream of each SNP)
were removed from consideration (Table S3). Following the
removal of all previously implicated loci [8–10], the quantile-
quantile plots show that some deviation remained between
observed and expected P values for high-signal SNPs suggesting
the presence of novel signals.
In the JMA of SNP and SNP-by-smoking in relation to FEV1/
FVC, we observed two novel loci containing several significant
SNP associations at the standard genome-wide Bonferroni-
corrected threshold of PJMA,5610
28, when considering interac-
tion with ever-smoking (Figure 1A) or pack-years (Figure 1B). The
SNP associations from both loci also exceeded the more
conservative genome-wide significance threshold of
PJMA,1.25610
28, based on additional Bonferroni correction for
the four JMA models.
The most statistically significant result was for rs7594321, an
intronic SNP located in DNER (delta/notch-like EGF-related
receptor) on chromosome 2, which gave PJMA= 2.64610
29
(corresponding PINT= 0.27) in the ever-smoking model and
PJMA= 5.00610
211 (corresponding PINT= 0.0069) in the pack-
years model (Table 1). For the ever/never-smoking interaction
model, the observed level of significance for the JMA is plausible in
the presence of a nominally significant SNP main effect and a
nonsignificant interactive effect, as detailed in Text S1. The
rs7594321 T allele had a positive b coefficient for the genetic main
association and a negative b coefficient for the interaction (Table 1,
Table S4 for study-specific results). The regression coefficients
correspond to a per allele change of 0.049 (95% CI: 0.030, 0.068)
in never-smokers and 0.035 (95% CI: 0.016, 0.053) in ever-
smokers. A conserved binding site for the Zic1 transcription factor
is located 115 base pairs away from rs7594321. Further,
rs7594321 is located upstream of the previously implicated PID1
gene (Figure 2A), but it is 713 kb away from the previously
implicated SNP (rs1435867), which is located downstream of
PID1. There is no linkage disequilibrium (LD) between rs7594321
and rs1435867 (r2 = 0, D9=0).
Our next most statistically significant SNP (rs7764819) is
intergenic between two human leukocyte antigen (HLA) genes,
HLA-DQB1 and HLA-DQA2, on chromosome 6 (Figure 2B). The
HLA-DQ region is highly variable, and the association signal in this
region is largely driven by two SNPs that are in high LD with one
another (rs7764819 and rs7765379, r2 = 1) but only low to
moderate LD with all other genotyped and imputed SNPs. A
GWAS meta-analysis of asthma implicating the HLA-DQ region
similarly found highly significant associations with only a few SNPs
[24]. Our top SNP rs7764819 gave PJMA= 4.39610
29 in the ever-
smoking model and PJMA= 4.35610
29 in the pack-years model
for FEV1/FVC (Table 1). The corresponding PINT values were
.0.05 (see Text S1). The rs7764819 T allele had negative b
coefficients for both the main association and interaction (Table 1,
Table S5 for study-specific results), which correspond to a SNP
effect of 20.060 (95% CI: 20.09, 20.031) in never-smokers and
20.070 (95% CI: 20.10, 20.042) in ever-smokers. Although
rs7764819 is located 529 kb away from a previously implicated
AGER SNP (rs2070600), there is some LD between the two SNPs
(r2 = 0.29, D9=0.81). Conserved binding sites for two transcrip-
tion factors, HTF and Lmo2, are located within 100 kb of
rs7764819.
Besides the DNER and HLA-DQB1/HLA-DQA2 loci, SNPs from
12 other chromosomal regions having PJMA values between
Author Summary
Measures of pulmonary function provide important clinical
tools for evaluating lung disease and its progression.
Genome-wide association studies have identified numer-
ous genetic risk factors for pulmonary function but have
not considered interaction with cigarette smoking, which
has consistently been shown to adversely impact pulmo-
nary function. In over 50,000 study participants of
European descent, we applied a recently developed joint
meta-analysis method to simultaneously test associations
of gene and gene-by-smoking interactions in relation to
two major clinical measures of pulmonary function. Using
this joint method to incorporate genetic main effects plus
gene-by-smoking interaction, we identified three novel
gene regions not previously related to pulmonary func-
tion: (1) DNER, (2) HLA-DQB1 and HLA-DQA2, and (3) KCNJ2
and SOX9. Expression analyses in human lung tissue from
ours or prior studies indicate that these regions contain
genes that are plausibly involved in pulmonary function.
This work highlights the utility of employing novel
methods for incorporating environmental interaction in
genome-wide association studies to identify novel genetic
regions.
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561028 and 161026 from either smoking model in relation to
FEV1/FVC are presented in Table S6. Secondary meta-analyses
of the interaction product terms alone identified no SNP-by-
smoking (ever-smoking or pack-years) interactions at genome-wide
statistical significance with FEV1/FVC. SNPs from two chromo-
somal regions had PINT values between 5610
28 and 161026 in
relation to FEV1/FVC, as shown in Table S7.
For FEV1, the JMA of SNP and SNP-by-smoking gave genome-
wide significant associations (PJMA,5610
28) in the ever-smoking
model for four SNPs on chromosome 17 (Figure 1C). However,
these SNP associations did not exceed the more conservative
significance threshold of PJMA,1.25610
28. No novel loci reached
genome-wide significance level in the pack-years model in relation
to FEV1 (Figure 1D).
The most significant SNP (rs11654749) from both smoking
models is intergenic between KCNJ2 (a potassium inwardly-
rectifying channel also known as KIR2.1) and SOX9 (sex
determining region Y-box 9) (Figure 2C). Conserved binding sites
for four transcription factors (HNF-1, CP2, Cdc5, and FOXF2)
are located within 100 kb upstream or downstream of rs11654749.
The rs11654749 SNP gave PJMA= 1.28610
28 in the ever-smoking
model and PJMA= 6.63610
28 in the pack-years model (Table 1).
The corresponding PINT values were .0.05 (see Text S1). The
rs11654749 T allele had negative b coefficients for both the main
association and interaction (Table 1, Table S8 for study-specific
results). These estimates correspond to a SNP effect of 20.028
(95% CI: 20.047, 20.010) in never-smokers and 20.046 (95%
CI: 20.063, 20.029) in ever-smokers. To better understand the
magnitude of these b estimates, we compared our results with
those observed in one of our previous GWAS meta-analyses of
SNP main effects [9], where standardized residuals of the
pulmonary function measures were similarly computed. For a
SNP with MAF around 40%, an absolute b value of 0.028 would
be equivalent to 19 mL per copy of the risk allele (comparable to a
year of FEV1 decline in healthy never-smokers), and an absolute b
value of 0.046 would be equivalent to 31 mL per copy of the risk
allele (comparable to a year and a half of FEV1 decline in healthy
never-smokers) [25].
Besides this KCNJ2/SOX9 locus, SNPs from five other
chromosomal regions have PJMA values between 5610
28 and
161026 from either smoking model in relation to FEV1 as shown
in Table S6. In secondary meta-analyses of the interaction product
terms, there were no SNP-by-smoking (ever-smoking or pack-
years) interactions implicated at genome-wide statistical signifi-
cance with FEV1. SNPs from four chromosomal regions had PINT
values between 561028 and 161026 in relation to FEV1, as
shown in Table S7.
None of the most significant SNPs from the three novel loci we
identified by the JMA were associated with FEV1/FVC or FEV1
at or near genome-wide significance in our previous GWAS meta-
analysis of 48,201 participants from the CHARGE and SpiroMeta
Consortia. In fact, the lowest P value observed for these SNPs was
1.0461025 (Table 2) [10].
To evaluate whether the three novel loci identified by the JMA
were related to smoking, we evaluated their SNP associations with
ever-smoking and cigarettes per day using GWAS meta-analysis
results from the Oxford-GlaxoSmithKline (Ox-GSK) Consortium
(N=41,150) [26]. None of our implicated SNPs were associated
Figure 1. Genome-wide joint meta-analysis (JMA) of SNP and SNP-by-smoking interaction in relation to pulmonary function. The
Manhattan plots show the chromosomal position of SNPs in comparison to their 2log10 PJMA values. JMA results are shown for models with (A) SNP-
by-ever-smoking interaction term in relation to FEV1/FVC, (B) SNP-by-pack-years interaction term in relation to FEV1/FVC, (C) SNP-by-ever-smoking
interaction term in relation to FEV1, and (D) SNP-by-pack-years interaction term in relation to FEV1. SNPs located within previously implicated loci are
shown, but these loci were not considered when identifying novel loci from the joint modeling of SNP main effects and smoking interactive effects.
Novel loci on chromosomes 2, 6, and 17 (shown in blue and circled) were identified as those having SNPs with genome-wide significant P values at
the standard threshold (P,561028 as indicated by the solid red line). Names of the novel gene (or closest genes) are provided.
doi:10.1371/journal.pgen.1003098.g001
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with these smoking phenotypes at P,0.05 (Table S9), adding
confidence that our JMA-implicated SNP associations were not
simply reflective of smoking main effects.
Expression analyses
Three genes (DNER, KCNJ2, and SOX9) harboring or flanking
novel genome-wide significant SNPs were selected for follow-up
mRNA expression profiling in human lung tissue and a series of
primary cells. Transcripts of all three genes were found in lung
tissue, airway smooth muscle, and bronchial epithelial cells; DNER
and KCNJ2 transcripts were also found in peripheral blood cells
(Table S10).
In a separate line of investigation, using the publically available
Gene Expression Omnibus repository [27,28], we found that the
expression profiling of DNER and SOX9 showed differential
expression in human airway epithelium of smokers compared to
non-smokers (Figure S2A and S2B) [29]. Expression profiling of
KCNJ2 did not show statistically significant differential expression
by smoking status (Figure S2C) [29]. We also identified novel
genome-wide significant SNPs in the HLA-DQ region, but we did
not examine HLA-DQ expression given the known expression of
class II MHC antigens on a range of airway cell types [30,31].
However, the lead SNP in this region (rs7764819) was associated
with statistically significant effects on HLA-DQB1 expression
(P=1.2610214), according to an eQTL analysis database of
lymphoblastoid cell lines [32].
Discussion
Few GWAS have accounted for potential interaction with
environmental risk factors. To identify novel genetic risk factors
that are missed when considering only genetic main effects [33],
we used the newly available JMA method [15] to simultaneously
summarize regression coefficients for the main SNP and SNP-by-
smoking interactive effects in 50,047 participants from 19 studies,
based on models that were fully saturated for the main effect of
smoking. This study represents the most comprehensive analysis to
date of gene-by-smoking interaction in relation to pulmonary
function. We identified two novel loci (DNER and HLA-DQB1/
HLA-DQA2) having highly significant evidence for association with
FEV1/FVC. A third novel locus (KCNJ2/SOX9) was associated
with FEV1. For the most significant SNPs at each of these three
loci, there was no evidence for heterogeneity across the studies
(smallest heterogeneity P=0.59), indicating that the associations
were not driven by one or a few studies and thus reflect
accumulation of evidence across the studies. None of these three
loci had previously been associated with pulmonary function. The
comparison of results with our prior GWAS meta-analysis of SNP
main effects [10], using a comparable sample size, suggested that
the SNP associations for our top SNPs were weaker in our
previous analyses that examined only genetic main effects.
However, our analyses and those of Manning et al. [14] suggest
that some of the benefit of using the joint test for some findings
comes from the careful adjustment for the environmental main
effect. Thus, future studies aimed at replicating these findings may
wish to jointly test the SNP main and interactive effects [15,16,33]
instead of implementing a standard test of only the SNP main
effects. If there is no evidence for interaction at a given locus, the
saturation of the main effect of the environmental factor may be
important. The joint testing is applicable for both candidate gene
[15] and genome-wide [14] approaches. Further, there was
minimal overlap in the top SNPs associated with FEV1/FVC
and FEV1, as similarly observed in our previous GWAS meta-
analyses of SNP main effects [8–10]. Given that the biological
underpinnings of these discrepant association findings remain
unknown, future studies should evaluate these genetic loci in the
context of the pulmonary function measure for which they were
originally implicated.
Given that pulmonary function is a phenotype for which
numerous genetic loci have been identified in GWAS and smoking
is clearly associated with pulmonary function, it might seem
surprising that none of the genome-wide significant SNPs
Table 1. Genome-wide significant SNPs from the joint meta-analysis (JMA) of SNP and SNP-by-smoking (ever-smoking or pack-
years) interaction in relation to pulmonary function.
SNP (coded
allele) Chr
Gene/closest
gene(s)
Coded allele
frequency1 JMA results
Smoking
metric bSNP
2 SESNP PSNP bINT
3 SEINT PINT PJMA
SNPs implicated in relation to FEV1/FVC
rs7594321 (T) 2q36.3 DNER 0.35 Ever-
smoking
0.049 0.0097 4.1461027 20.015 0.013 0.27 2.6461029
Pack-years 0.048 0.0070 7.03610212 20.00020 0.000074 6.8861023 5.00610211
rs7764819 (T) 6p21.32 HLA-DQB1/HLA-
DQA2
0.89 Ever-
smoking
20.060 0.015 6.3261025 20.0010 0.021 0.63 4.3961029
Pack-years 20.064 0.011 5.9561029 20.000058 0.00010 0.56 4.3561029
SNPs implicated in relation to FEV1
rs11654749 (T) 17q24.3 KCNJ2/SOX9 0.39 Ever-
smoking
20.028 0.0094 2.4661023 20.017 0.013 0.17 1.2861028
Pack-years 20.038 0.0068 2.2961028 0.000047 0.000068 0.49 6.6361028
After removing SNPs with known associations with FEV1/FVC or FEV1, three novel loci with genome-wide significant SNPs (standard threshold of P,5610
28) remained
from the JMA testing in the current study. The most significant SNP from each locus is shown.
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; JMA, joint meta-analysis; SE, standard error ; SNP, single nucleotide polymorphism.
1Weighted average coded allele frequency across the 19 studies. The coded allele refers to the effect allele.
2bSNP, per allele change in the FEV1/FVC standardized residual due to the SNP main association.
3bINT, per allele change in the FEV1/FVC standardized residual due to the interaction between SNP and smoking.
doi:10.1371/journal.pgen.1003098.t001
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implicated by the JMA demonstrated a substantial interaction per
se. The lack of strong interactive effects does not negate the well-
established harmful effects of cigarette smoking nor the need for
broad public health campaigns to curb smoking. Instead, our
findings demonstrate the value of applying the newly developed
joint methods to uncover novel genetic risk factors that might shed
light on the mechanisms leading to reduced pulmonary function.
Our pattern of SNP main and interactive results resemble the
patterns seen in another recent application of the same JMA
method to incorporate the interaction with body mass index (BMI)
into GWAS of type 2 diabetes traits (fasting insulin and blood
glucose) [14]. In that study with a sample size of 96,453, nearly
double that of ours, the top JMA finding had a corresponding
interaction P value of 1.661024 [14]. In our study, the smallest
interaction P value for our top JMA finding was 6.961023. In both
our GWAS of smoking and pulmonary function and the recent
GWAS of BMI and diabetes traits [14], the SNPs newly implicated
by the JMA had marginally significant associations with the trait
under study in models with no interaction term, but they became
genome-wide significant when accounting for the environmental
factor (cigarette smoking or BMI) and the SNP-by-environment
interaction. Our JMA included careful modeling of the environ-
mental factor to saturate the environmental main effects along
with the interaction testing. In the GWAS of diabetes traits [14],
the careful modeling of the environmental factor appeared to
account for some of the novel findings from the JMA, consistent
with the modest evidence for interaction [14]. Although our
previous GWAS meta-analysis was conducted in ever/never-
smoking strata, the regression models were not adjusted for
smoking status or pack-years [10]. Some of our novel JMA
findings compared with our previous GWAS findings may reflect,
in part, the saturated modeling of the smoking main effect rather
than the interaction per se.
The current analysis of 50,047 participants included only 1,846
more participants than our previous GWAS meta-analysis of SNP
main effects [10]. To evaluate the likelihood that this 3.8%
increase in sample size above that in our previous meta-analysis of
pulmonary function was sufficient to explain our identification of
these three novel loci at genome-wide statistical significance in the
current JMA, we calculated the statistical power to detect genetic
main associations (QUANTO [34]) with minor allele frequency
(MAF) and b estimates comparable to the three genome-wide
significant SNPs presented in Table 1. The current study (total
N= 50,047 participants) had only 0.7% to 4.2% more statistical
power than our previous GWAS meta-analysis (total N= 48,201
participants) [10], suggesting that the JMA-implicated SNPs are
not merely reflective of increased power to detect genetic main
effects. Instead, our novel JMA findings demonstrate an advantage
of the method used to jointly test the SNP and SNP-by-smoking
interactive effects, including the benefit of the saturated modeling
of the smoking main effect.
SNPs located in the DNER gene were significantly associated
with FEV1/FVC, even at the more conservative P value threshold
of 1.2561028. The JMA results for DNER SNPs were driven by
both smoking-adjusted main effects and interaction with quanti-
tative smoking history. The DNER protein product is a ligand of
the Notch signaling pathway that has been implicated in neuronal
differentiation and maturation [35,36], adipogenesis [37], and
hair-cell development [38]. The Notch pathway is a critical
controller of cellular differentiation in multiple organs including
the lung [39,40]. Interestingly, the expression levels of many
members of the Notch signaling cascade are significantly altered in
airway epithelial cells of smokers [41]. We confirmed the
expression of DNER transcripts in lung and peripheral cells, and
by mining publicly available transcriptional profiling databases
[29], we found that DNER is expressed in bronchial epithelial cells
of non-smoking adults and, importantly, its expression is
significantly higher in smokers (Figure S2A). Collectively, these
results suggest that DNER plays a role in cigarette smoke-induced
Figure 2. Regional association plots of novel loci implicated for
pulmonary function. Three novel loci contained SNPs associated
with FEV1/FVC or FEV1 at the standard genome-wide significance
threshold (P,561028) in joint meta-analyses of SNP and SNP-by-
smoking interaction. SNPs are shown within 500 kb of the most
significant SNPs on chromosomes (A) 2q36.3 associated with FEV1/FVC,
(B) 6p21.32 associated with FEV1/FVC, and (C) 17q24.3 associated with
FEV1. Pairwise r
2 values were based on the HapMap CEU population,
and progressively darker shades of red indicate higher r2 values.
Estimated recombination rates from HapMap are shown as background
lines.
doi:10.1371/journal.pgen.1003098.g002
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airflow obstruction and further corroborate the importance of the
Notch signaling circuitry in the pathogenesis of obstructive lung
disease.
Also in relation to FEV1/FVC, intergenic SNPs between HLA-
DQB1 and HLA-DQA2 exceeded the more conservative genome-
wide significance threshold. The eQTL analyses indicated that the
lead SNP is associated with expression of HLA-DQB1 specifically.
However, the major histocompatibility complex region is highly
polymorphic with complex LD patterns, and a few specific
functional SNPs might explain the observed associations [42].
Genetic variations within this region have been associated with
several autoimmune disorders [43] and asthma [24,44,45], and an
interaction between HLA variants and cigarette smoking has been
previously implicated [46]. We found little evidence for interaction
with smoking at this locus, suggesting that the JMA results were
primarily driven by smoking-adjusted genetic main effects. It is
most likely that this locus was not identified in our previous GWAS
meta-analysis, because the genetic main associations were not
evaluated with careful adjustment for smoking status and pack-
years. Adjustment for smoking in the current analysis may have
removed residual variance in the outcome that is not attributable
to genetic variation [14], thus making the identification of the
newly associated SNPs possible.
Intergenic SNPs between KCNJ2 and SOX9 were significantly
associated with FEV1 at the standard P value threshold, but not
the more conservative threshold. Similar to the HLA region, it
appears that the JMA results for the KCNJ2/SOX9 region were
primarily driven by smoking-adjusted genetic main effects. This
region is enriched for long-range regulatory elements for SOX9,
although the possibility of this region containing KCNJ2 regulatory
elements cannot be discounted [47]. KCNJ2 is a member of the
inwardly-rectifying potassium channel family, which regulates
membrane potential and cell excitability and is expressed in many
tissues including myocardium, neurons, and vasculature. This
potassium channel also affects human bronchial smooth muscle
tone and airflow limitation [48]. Dominant negative mutations in
KCNJ2 cause the Andersen syndrome, characterized by ventricular
arrhythmias, periodic paralysis, and a number of skeletal and
cardiac abnormalities [49]. SOX9 is a transcription factor that is
essential for cartilage formation, [50] but it is also abundantly
expressed in other tissues including the respiratory epithelium
during development [51]. Sox92/2 and Sox9+/2 mice have
multiple skeletal anomalies and severe tracheal cartilage malfor-
mations and die prematurely from respiratory insufficiency
[50,52]. Mutations in SOX9 cause campomelic dysplasia charac-
terized by skeletal defects and autosomal sex reversal [53]. These
individuals develop respiratory distress due to chest wall abnor-
malities, narrowed airways resulting from tracheobronchial defects
and hypoplastic lungs [54]. We confirmed that KCNJ2 and SOX9
transcripts were present in human lung tissue and peripheral cells.
Using publicly available microarray data [29], we established that
SOX9 is expressed in human airway epithelial cells and its
expression is significantly down-regulated in smokers relative to
non-smoking adults (Figure S2B). Taken together, these results
suggest that SOX9 may be involved in cigarette smoke-induced
airflow obstruction, but further investigation is required to
elucidate putative mechanisms.
Most of the previously implicated SNPs had genome-wide
significant (or nearly significant) associations with pulmonary
function in the JMA, but some were associated with pulmonary
function at P values that did not approach the genome-wide
statistical significance threshold in the JMA analysis. This pattern
has two possible explanations. First, the identification of these
SNPs at genome-wide statistical significance in our most recent
analysis [10] required a sample size of nearly 95,000 individuals,
which was obtained by combining discovery and replication
cohorts, including additional genotyping on thousands of
participants from studies without GWAS data. In the current
analysis, the sample size is greatly reduced because of the need for
detailed quantitative smoking data and because we were unable to
perform additional genotyping in studies without GWAS data.
Second, Manning et al.[15] showed that a meta-analysis of main
SNP effects has slightly greater power than the JMA under the
scenario of no interaction, so it is not surprising that a few of the
prior SNP findings had varying levels of significance between our
prior GWAS meta-analyses [8–10] and the current JMA study.
While our sample size of over 50,000 study participants is large, and
the study of Manning et al. [14] examining SNP-by-BMI
interaction in relation to fasting insulin is nearly twice as large,
identification of interactions is challenging from a statistical power
perspective. Given the multiple testing issues in genome interaction
testing, even larger sample sizes will likely be needed to identify
gene-by-environment interactions with rare variants or with the
modest effect sizes that we generally expect. Nonetheless, our
findings exemplify the greater power achieved by using the joint
methods, such as those reported by Manning et al. [15] and Kraft et
al. [16,33], to incorporate interaction with a clearly associated
environmental risk factor. The novel genetic loci identified here for
pulmonary function would have remained unknown using standard
GWAS approaches.
Methods
Ethics statement
Nineteen independent studies contributed to our analyses. All
study protocols were approved by the respective local Institutional
Table 2. Look-up evaluation of SNP main associations with FEV1/FVC and FEV1 using data generated by our previous genome-
wide association study meta-analysis (N = 48,201), for the most significant SNP from each of the three novel loci implicated at
genome-wide significance in the joint meta-analysis.
SNP (coded allele) Gene/closest gene(s) FEV1/FVC FEV1
b1 SE P b1 SE P
rs7594321 (T) DNER 0.032 0.0072 1.0461025 0.0081 0.0074 0.27
rs7764819 (T) HLA-DQB1/HLA-DQA2 20.044 0.011 8.7961025 20.0073 0.011 0.52
rs11654749 (T) KCNJ2/SOX9 20.023 0.0071 0.0015 20.031 0.0072 1.2361025
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; SE, standard error; SNP, single nucleotide polymorphism.
1bSNP, per allele change in the FEV1/FVC standardized residual due to the SNP main association.
doi:10.1371/journal.pgen.1003098.t002
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Review Boards, and written informed consent for genetic studies
was obtained from all participants included in our analyses.
Cohort studies
Of the 19 studies contributing to our analyses, 18 studies came
from the CHARGE [8,55] or SpiroMeta [9] Consortium: Age,
Gene, Environment, Susceptibility (AGES) – Reykjavik Study
[56]; Atherosclerosis Risk in Communities (ARIC) Study [57];
British 1958 Birth Cohort (B58C) [58]; Coronary Artery Risk
Development in Young Adults (CARDIA) [59,60]; Cardiovascular
Health Study (CHS) [61]; European Community Respiratory
Health Survey (ECRHS) [62]; European Prospective Investigation
into Cancer and Nutrition (EPIC, obese cases and population-
based subsets) [63]; Framingham Heart Study (FHS) [64,65];
Health, Aging, and Body Composition (Health ABC) Study [66];
Northern Finland Birth Cohort of 1966 (NFBC1966) [67,68];
Multi-Ethnic Study of Atherosclerosis (MESA) [69,70]; Rotterdam
Study (RS-I, RS-II, and RS-III) [71]; Swiss Study on Air Pollution
and Lung Diseases in Adults (SAPALDIA) [72]; Study of Health in
Pomerania (SHIP) [73]; and TwinsUK [74]. We reached out to
other population-based studies with GWAS genotyping and data
available on cigarette smoking and pulmonary function, resulting
in the inclusion of LifeLines [75]. Given the greater power needed
to detect novel genetic loci with subtle gene-environment
interaction regardless of the statistical method used [16], we chose
to maximize statistical power to discover novel genetic loci by
combining all available participants and to use the regression
coefficients across the many different component studies as
evidence for consistency. This approach was similarly taken by
another large-scale GWAS consortium for discovering SNP main
effects [24].
Pulmonary function measurements and smoking
information
All studies were included in our previous GWAS meta-analysis of
pulmonary function or the follow-up replication analyses, wherein
their pulmonary function testing protocols were described [10]. For
studies with spirometry at a single visit (B58C, LifeLines, MESA,
NFBC1966, SHIP, RS-I, RS-II, and RS-III), we analyzed FEV1/
FVC and FEV1 measured at that visit. For studies with spirometry
at more than one visit, we analyzed measurements from the baseline
visit (AGES, ARIC, CARDIA, CHS, ECRHS, EPIC obese cases,
EPIC population-based, Health ABC, and SAPALDIA) or the most
recent examination with spirometry data (FHS and TwinsUK).
Smoking history (current-, past-, and never-smoking) was
ascertained by questionnaire at the time of pulmonary function
testing. Pack-years of smoking were calculated for current and past
smokers by multiplying smoking amount (packs/day) and duration
(years smoked). Table S11 presents the specific questions used to
ascertain smoking history and pack-years in each of the 19 studies.
Genotyping, quality control, and imputation
Study participants were genotyped on various genotyping
platforms, and standard quality control filters for call rate, Hardy-
Weinberg equilibrium p-value, MAF, and other measures were
applied to the genotyped SNPs (Table S12). To generate a common
set of SNPs for meta-analysis, imputation was conducted with
reference haplotype panels from HapMap phase II subjects of
European ancestry (CEU) (Table S12) [76]. Imputed genotype
dosage values (estimated reference allele count with a fractional
value ranging from 0 to 2.0) were generated for approximately 2.5
million autosomal SNPs. Among participants with genome-wide
SNP genotyping data, exclusions were made due to standard quality
control metrics (call rate, discordance with prior genotyping, and
genotypic and phenotypic sex mismatch among others), missing
pulmonary function data, or missing covariate data (Table S13).
Statistical analysis
Our analyses included 50,047 participants from 19 studies who
passed their study-specific quality control and had complete data
on pulmonary function and smoking. Each study transformed the
pulmonary function measures to residuals using linear regression
of FEV1/FVC (%) and FEV1 (mL) on age, age
2, sex, and standing
height as predictors. Principal component eigenvectors and
recruitment site were also included as covariates to adjust for
population stratification (if applicable). The residuals were
converted to z scores (henceforth referred to as standardized
residuals). We confirmed that smoking was inversely associated
with the FEV1/FVC and FEV1 standardized residuals in all 19
studies (meta-analysis b=20.0030 and corresponding P,161026
for pack-years of smoking).
The FEV1/FVC and FEV1 standardized residuals were used as
the phenotypes for genome-wide association testing with linear
regression models, which included the following predictor variables:
imputed SNP genotype dosages, smoking history (dichotomous
variable, 0 = never-smokers and 1= ever-smokers), smoking status
(dichotomous variable, 0= never- and past-smokers and 1= cur-
rent-smokers), pack-years of smoking (continuous variable), and a
SNP-by-smoking interaction product term. Two of the 19 studies
(FHS and TwinsUK) had much relatedness among participants,
and we took appropriate account of relatedness in the association
testing (Table S12). Four regression models with interaction terms
for ever-smoking or pack-years were specified in relation to
standardized residuals for FEV1/FVC or FEV1. As it has long
been advised in studying interactions, the regression models were
designed to fully saturate the main smoking effect on pulmonary
function, so that the interaction terms do not capture residual main
effects [77]. In each of the 19 studies, the genome-wide analyses
were implemented with robust variance estimation using the
software packages indicated in Table S12.
Our analyses were aimed at finding novel loci associated with
pulmonary function when considering an interaction with
cigarette smoking, so we chose to implement JMA of SNP main
and interactive SNP-by-smoking effects (two d.f. test of the null
hypothesis bSNP = 0 and bINT= 0) [15]. Manning et al. previously
compared the joint methods, such as JMA, with other methods
that incorporate gene-environment interaction (such as screening
by main effects [78] or conducting a 1 d.f. meta-analysis of the
interaction product term), and they found that the joint methods
offer optimal statistical power over a range of scenarios for SNP
main and interactive effects [15,33]. Therefore, our analyses
centered on the JMA method, which simultaneously estimates
regression coefficients for the SNP and SNP-by-smoking interac-
tion terms, while accounting for their covariance, to generate a
joint test of significance [15]. It also accounts for the unequal
variances from studies of different sample sizes. Secondarily, we
implemented meta-analyses of just the b coefficient from the
interaction term for comparison with the JMA results. Of note, the
two-step gene-environment interaction study designs by Murcray
et al. [79,80] and Gauderman et al. [81] are applicable to case-
control or case-parent trio studies, respectively, and were thus not
considered for our population-based studies of continuous traits.
The JMA was conducted with fixed effects on approximately 2.5
million SNPs using METAL software (version 2010-02-08) [82]
and patch source code provided by Manning et al. [82]. Genomic
control correction was applied by computing lgc as the ratio of the
observed and expected (2 d.f.) median chi-square statistics and
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dividing the observed chi-square statistics by lgc. SNPs having
PJMA,5610
28 (the standard Bonferroni-adjusted P value) were
considered statistically significant [83]. Further correction for the
four different (albeit related) JMA models yielded a conservative
PJMA threshold of 1.25610
28. In addition to reporting the PJMA
for the most significant SNP from each novel locus, we used the b
and standard error (SE) estimates from the JMA results to calculate
the P values corresponding to the SNP main association (PSNP) and
the SNP-by-ever-smoking interaction (PINT) [15].
Bioinformatics analysis
Gene annotation was performed using the gene prediction
tracks ‘‘UCSC Genes’’ and ‘‘RefSeq Genes’’ in the UCSC browser
(http://genome.ucsc.edu). The ‘‘sno/miRNA’’ track from the
USCS browser was used to search for any microRNA within
100 kb upstream or downstream of each SNP, and the ‘‘TFBS
Conserved’’ track was used to search for conserved transcription
factor binding sites (TFBSs) at or near the most significant SNPs.
The SNAP program [84] was used to infer LD patterns, based on
the HapMap phase II CEU population.
Expression analyses
We used separate types of expression analyses to confirm the
biologic plausibility of our findings. First, we carried out mRNA
expression profiling to show whether or not the implicated genes are
expressed in human tissues relevant to pulmonary function. The
mRNA expression profiles of implicated genes were determined
using reverse transcription polymerase chain reaction (RT-PCR).
RNA was sourced from lung (Ambion/ABI), human bronchial
epithelial cells (Clonetics) [85], and peripheral blood mononuclear
cells (3H Biomedica). RNA from human airway smooth muscle cells,
cultured as previously described from tissue obtained at thoracotomy
[86], was extracted using a commercially available kit (Qiagen).
Ethical approval for the use of primary cells was obtained from the
local ethics committees. cDNA was generated using 1 mg of RNA
template using random hexamers and a SuperScript kit (Invitrogen)
as directed by the manufacturer. PCR assays were designed to cross
intron-exon boundaries, where possible and where splice variation
was known, in order to detect all variants. The GAPDH gene was
used as a positive control for the cDNA quality, and water was used
as a negative control. Primer sequences for the genes of interest are
given in Table S14. All PCR were done using Platinum Taq High
Fidelity (Invitrogen) with 100 ng of cDNA template in a 25 mL
reaction. Cycling conditions were as follows: 94uC for 2 minutes, 35
cycles of 94uC for 45 seconds, 55uC for 30 seconds, and 68uC for
90 seconds. Following PCR, gel bands were directly sequenced to
confirm the presence of the gene’s transcript.
Second, we used another publically available data repository to
investigate whether any of the implicated genes showed evidence
for differential expression depending on smoking history. The gene
expression profiles of human airway epithelium from healthy
smokers (N= 10) and nonsmokers (N=12) were obtained from the
Gene Expression Omnibus site (http://www.ncbi.nlm.nih.gov/
geo/) [27,28], based on robust multichip average processing of
probe intensities from Affymetrix HG-U133 Plus 2.0 microarrays
(GEO dataset number GSE4498) [29]. Mean expression levels of
genes around our genome-wide significant findings from the JMA
were compared between smokers versus nonsmokers. The P value
for the difference in means between smokers and nonsmokers was
calculated using the nonparametric Mann-Whitney test.
Third, our genome-wide significant SNPs from novel loci were
searched against an expression quantitative trait loci (eQTL) data
repository based on lymphoblastoid cell lines [32], to investigate
whether any of the implicated SNP variants might influence the
expression of the nearby genes. P,561028 was used to designate
statistically significant eQTL associations.
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